NASDAQ:BDTX Black Diamond Therapeutics (BDTX) Stock Price, News & Analysis → The Long-Awaited End of America Update (From Stansberry Research) (Ad) Free bdtx Stock Alerts $6.59 +0.69 (+11.69%) (As of 05/2/2024 ET) Add Compare Share Share Today's Range$5.89▼$6.7550-Day Range$3.78▼$5.9052-Week Range$1.45▼$6.85Volume1.29 million shsAverage Volume612,689 shsMarket Capitalization$346.17 millionP/E RatioN/ADividend YieldN/APrice Target$12.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Black Diamond Therapeutics alerts: Email Address Black Diamond Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside85.9% Upside$12.25 Price TargetShort InterestHealthy3.35% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.71) to ($1.79) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.78 out of 5 starsMedical Sector408th out of 908 stocksBiological Products, Except Diagnostic Industry57th out of 149 stocks 3.5 Analyst's Opinion Consensus RatingBlack Diamond Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageBlack Diamond Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted3.35% of the outstanding shares of Black Diamond Therapeutics have been sold short.Short Interest Ratio / Days to CoverBlack Diamond Therapeutics has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Black Diamond Therapeutics has recently decreased by 13.73%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldBlack Diamond Therapeutics does not currently pay a dividend.Dividend GrowthBlack Diamond Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BDTX. Previous Next 2.9 News and Social Media Coverage News SentimentBlack Diamond Therapeutics has a news sentiment score of 1.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.32 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Black Diamond Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 3 people have searched for BDTX on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat Follows7 people have added Black Diamond Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 75% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Black Diamond Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.07% of the stock of Black Diamond Therapeutics is held by insiders.Percentage Held by Institutions95.47% of the stock of Black Diamond Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Black Diamond Therapeutics are expected to decrease in the coming year, from ($1.71) to ($1.79) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Black Diamond Therapeutics is -3.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Black Diamond Therapeutics is -3.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBlack Diamond Therapeutics has a P/B Ratio of 2.92. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry Research$5,000 Gold?Former Wall Street Banker Reveals Mysterious Gold Leverage As gold continues to soar, this ex-Goldman Sachs VP says DON'T buy bullion or mining stocks. Instead, he's just shared a "gold bank" that uses about $10 of your money to harness the power of two ounces of pure gold (worth about $4,200 right now).Find out how to do right here in this free video. About Black Diamond Therapeutics Stock (NASDAQ:BDTX)Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.Read More BDTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BDTX Stock News HeadlinesApril 24, 2024 | globenewswire.comBlack Diamond Therapeutics Announces Presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingApril 11, 2024 | globenewswire.comBlack Diamond Therapeutics Announces Changes to Board of DirectorsMay 2, 2024 | Stansberry Research (Ad)The Long-Awaited End of America UpdateA 995% Gain Last Time We Shared this "Election Secret" It's a straightforward way to come out on top no matter who wins this November… It's not cryptos, or options, and anyone can do it.April 8, 2024 | finance.yahoo.comWall Street Analysts Predict a 129.25% Upside in Black Diamond (BDTX): Here's What You Should KnowApril 7, 2024 | globenewswire.comBlack Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual MeetingApril 3, 2024 | globenewswire.comBlack Diamond Therapeutics to Participate in Upcoming Investor ConferencesMarch 14, 2024 | finance.yahoo.comBlack Diamond Therapeutics Inc (BDTX) Reports Q4 and Full Year 2023 Financials, Advances ...March 12, 2024 | globenewswire.comBlack Diamond Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateMay 2, 2024 | Stansberry Research (Ad)The Long-Awaited End of America UpdateA 995% Gain Last Time We Shared this "Election Secret" It's a straightforward way to come out on top no matter who wins this November… It's not cryptos, or options, and anyone can do it.March 5, 2024 | globenewswire.comBlack Diamond Therapeutics Announces Upcoming Presentation at AACR Annual Meeting 2024February 29, 2024 | seekingalpha.comBDTX Black Diamond Therapeutics, Inc.February 28, 2024 | globenewswire.comBlack Diamond Therapeutics to Participate in the TD Cowen 44th Annual Health Care ConferenceFebruary 16, 2024 | uk.investing.comBlack Diamond Therapeutics Inc (BDTX)January 24, 2024 | wsj.comBlack Diamond Therapeutics Inc.January 4, 2024 | finance.yahoo.comBlack Diamond Therapeutics Announces Corporate Update and Expected 2024 MilestonesDecember 14, 2023 | msn.comBlack Diamond reports positive topline data for GBM drugDecember 14, 2023 | markets.businessinsider.comBuy Rating Reaffirmed for Black Diamond Therapeutics Amid Promising BDTX-1535 Trial Results and Strategic DevelopmentDecember 13, 2023 | finance.yahoo.comBlack Diamond Therapeutics Announces Topline Results from Phase 1 Dose Escalation Trial of BDTX-1535 in Patients with Recurrent GBMDecember 5, 2023 | finance.yahoo.comWith 58% ownership, Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) boasts of strong institutional backingNovember 9, 2023 | washingtonpost.comSolitario: Q3 Earnings SnapshotNovember 6, 2023 | finance.yahoo.comBlack Diamond Therapeutics Inc (BDTX) Reports Q3 2023 Financial Results and Corporate UpdateNovember 6, 2023 | finance.yahoo.comBlack Diamond Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateOctober 31, 2023 | morningstar.comBlack Diamond Therapeutics Inc Ordinary Shares BDTXOctober 17, 2023 | markets.businessinsider.comAnalysts’ Top Healthcare Picks: Black Diamond Therapeutics (BDTX), Ultragenyx Pharmaceutical (RARE)October 16, 2023 | markets.businessinsider.comBlack Diamond Therapeutics (BDTX) Receives a Buy from Piper SandlerOctober 14, 2023 | finance.yahoo.comBlack Diamond Therapeutics Presents Dose Escalation Data Demonstrating Durable Responses in Patients with NSCLC from Phase 1 Trial of BDTX-1535October 12, 2023 | msn.comBlack Diamond's BDTX-1535: A Brainy Bet In Cancer TherapySee More Headlines Receive BDTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Black Diamond Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/12/2024Today5/02/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:BDTX CUSIPN/A CIK1701541 WebN/A Phone617-252-0848FaxN/AEmployees54Year FoundedN/APrice Target and Rating Average Stock Price Target$12.25 High Stock Price Target$16.00 Low Stock Price Target$10.00 Potential Upside/Downside+95.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.88) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-82,440,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-76.43% Return on Assets-56.24% Debt Debt-to-Equity RatioN/A Current Ratio6.82 Quick Ratio6.82 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.26 per share Price / Book2.77Miscellaneous Outstanding Shares52,530,000Free Float47,766,000Market Cap$328.84 million OptionableOptionable Beta2.56 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesDr. Mark A. Velleca M.D. (Age 60)Ph.D., CEO, President & Chairman Comp: $43.89kDr. David M. Epstein Ph.D. (Age 65)Co-Founder & Director Comp: $885.08kDr. Fang Ni Pharm.D. (Age 37)CFO, Principal Financial Officer and Chief Business Officer Comp: $656.33kMr. Brent Hatzis-Schoch Esq. (Age 59)J.D., COO & General Counsel Comp: $683.29kDr. Elizabeth Buck Ph.D. (Age 49)Co-Founder & Chief Scientific Officer Comp: $340.47kMs. Erika Jones (Age 39)VP of Finance, Corporate Controller & Principal Accounting Officer Ms. Elizabeth L. Montgomery (Age 52)Chief People Officer Dr. Sergey Yurasov M.D. (Age 55)Ph.D., Chief Medical Officer Ms. Melanie MorrisonChief Development OfficerMore ExecutivesKey CompetitorsAdaptimmune TherapeuticsNASDAQ:ADAPAnavex Life SciencesNASDAQ:AVXLMeiraGTxNASDAQ:MGTXMonte Rosa TherapeuticsNASDAQ:GLUEInvivydNASDAQ:IVVDView All CompetitorsInsiders & InstitutionsBellevue Group AGBought 400,000 shares on 2/14/2024Ownership: 16.533%Pale Fire Capital SEBought 51,100 shares on 2/14/2024Ownership: 0.099%Jump Financial LLCBought 27,616 shares on 2/7/2024Ownership: 0.075%Simplex Trading LLCBought 600 shares on 2/2/2024Ownership: 0.000%Growth N V BiotechBought 400,000 shares on 10/17/2023Total: $936,000.00 ($2.34/share)View All Insider TransactionsView All Institutional Transactions BDTX Stock Analysis - Frequently Asked Questions Should I buy or sell Black Diamond Therapeutics stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Black Diamond Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BDTX shares. View BDTX analyst ratings or view top-rated stocks. What is Black Diamond Therapeutics' stock price target for 2024? 4 brokers have issued twelve-month price objectives for Black Diamond Therapeutics' stock. Their BDTX share price targets range from $10.00 to $16.00. On average, they expect the company's stock price to reach $12.25 in the next twelve months. This suggests a possible upside of 85.9% from the stock's current price. View analysts price targets for BDTX or view top-rated stocks among Wall Street analysts. How have BDTX shares performed in 2024? Black Diamond Therapeutics' stock was trading at $2.81 at the beginning of 2024. Since then, BDTX stock has increased by 134.5% and is now trading at $6.59. View the best growth stocks for 2024 here. Are investors shorting Black Diamond Therapeutics? Black Diamond Therapeutics saw a decline in short interest during the month of April. As of April 15th, there was short interest totaling 1,760,000 shares, a decline of 13.7% from the March 31st total of 2,040,000 shares. Based on an average trading volume of 629,900 shares, the days-to-cover ratio is currently 2.8 days. View Black Diamond Therapeutics' Short Interest. When is Black Diamond Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our BDTX earnings forecast. How were Black Diamond Therapeutics' earnings last quarter? Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) issued its quarterly earnings data on Tuesday, March, 12th. The company reported ($0.34) earnings per share for the quarter, topping analysts' consensus estimates of ($0.47) by $0.13. What other stocks do shareholders of Black Diamond Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Black Diamond Therapeutics investors own include Alector (ALEC), Alteryx (AYX), Editas Medicine (EDIT), Gossamer Bio (GOSS), Micron Technology (MU), NVIDIA (NVDA), Homology Medicines (FIXX), II-VI (IIVI), Intel (INTC) and Invitae (NVTA). When did Black Diamond Therapeutics IPO? Black Diamond Therapeutics (BDTX) raised $151 million in an IPO on Thursday, January 30th 2020. The company issued 8,900,000 shares at $16.00-$18.00 per share. J.P. Morgan, Jefferies and Cowen served as the underwriters for the IPO and Canaccord Genuity was co-manager. Who are Black Diamond Therapeutics' major shareholders? Black Diamond Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Ali Behbahani, Brent Hatzis-Schoch, Christopher D Roberts, David M Epstein, Fang Ni and Growth N V Biotech. View institutional ownership trends. How do I buy shares of Black Diamond Therapeutics? Shares of BDTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BDTX) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersUrgent Nvidia WarningAltimetryA.I. is a Tidal Wave - Here’s What to BuyChaikin AnalyticsTruth about Trump you’ve never heardPorter & CompanyHe Is Giving Away BitcoinCrypto Swap ProfitsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThe A.I. story nobody is telling you (Read ASAP)TradeSmithAI “wealth window” is closing June 25thParadigm Press4 Cryptos BETTER than BitcoinTrue Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Black Diamond Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.